| 夏冬丽,沈文拥,魏 沙,易志强,刘爱民.胶体果胶铋胶囊联合维酶素片对慢性萎缩性胃炎患者血清胃蛋白酶原和炎症因子的影响[J].,2021,(23):4541-4544 |
| 胶体果胶铋胶囊联合维酶素片对慢性萎缩性胃炎患者血清胃蛋白酶原和炎症因子的影响 |
| Effects of Colloidal Pectin Bismuth Capsule Combined with Vitacoenzyme Tablets on Serum Pepsinogen and Inflammatory Factors in Patients with Chronic Atrophic Gastritis |
| 投稿时间：2021-04-03 修订日期：2021-04-28 |
| DOI：10.13241/j.cnki.pmb.2021.23.030 |
| 中文关键词: 胶体果胶铋胶囊 维酶素片 慢性萎缩性胃炎 胃蛋白酶原 炎症因子 |
| 英文关键词: Colloidal pectin bismuth capsule Vitacoenzyme Tablets Chronic atrophic gastritis Pepsinogen Inflammatory factor |
| 基金项目:重庆市卫计委医学科研项目（2017ZDXM006） |
|
| 摘要点击次数: 840 |
| 全文下载次数: 495 |
| 中文摘要: |
| 摘要 目的：观察胶体果胶铋胶囊联合维酶素片对慢性萎缩性胃炎（CAG）患者血清胃蛋白酶原和炎症因子的影响。方法：选取重庆大学附属涪陵医院于2019年4月~2021年3月期间收治的CAG患者98例，按照双色球法将患者分别对照组（n=49）和实验组（n=49），对照组、实验组患者分贝接受维酶素片、胶体果胶铋胶囊联合维酶素片治疗，两组均治疗4周。观察两组疗效和血清胃蛋白酶原Ⅰ（PGⅠ）、胃蛋白酶原Ⅱ（PGⅡ）、胃泌素-17（G-17）、白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、可溶性白细胞介素-2受体（sIL-2R）、肿瘤坏死因子-α（TNF-α）的变化情况，记录两组用药安全性。结果：经治疗，对照组的临床总有效率为71.43%，低于实验组的93.88%（P<0.05）。治疗结束后，两组PGⅡ较治疗前下降，PGⅠ、G-17均较治疗前升高（P<0.05），且实验组的PGⅠ、PGⅡ、G-17变化更为明显（P<0.05）。治疗结束后，两组炎性因子指标：IL-6、hs-CRP、sIL-2R、TNF-α均较治疗前下降（P<0.05），且实验组的炎性因子指标变化更为明显（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。结论：胶体果胶铋胶囊联合维酶素片治疗CAG患者，具有显著的治疗效果，可有效调节机体胃黏膜相关和炎症因子水平，且不增加不良反应发生率，临床应用价值较好。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effects of colloidal pectin bismuth capsule combined with vitacoenzyme tablets on serum pepsinogen and inflammatory factors in patients with chronic atrophic gastritis (CAG). Methods: 98 patients with CAG who were treated in Fuling Hospital Affiliated to Chongqing University from April 2019 to March 2021 were selected. According to the two-color ball method, the patients were divided into control group (n=49) and experimental group (n=49). The patients in the control group and the experimental group received vitacoenzyme tablets, colloidal pectin bismuth capsule combined with vitacoenzyme tablets, both groups were treated for 4 weeks. The curative effects and the changes of serum pepsinogen I (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (G-17), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in the two groups were observed. The drug safety of the two groups was recorded. Results: After treatment, the total clinical effective rate of the control group was 71.43%, which was lower than 93.88% of the experimental group (P<0.05). After treatment, PG Ⅱ in the two groups decreased compared with that before treatment, PG Ⅰ and G-17 increased compared with those before treatment (P<0.05), and the changes of PGⅠ, PGⅡ and G-17 in the experimental group were more obvious (P<0.05). After treatment, the inflammatory factor indexes of IL-6, hs-CRP, sIL-2R and TNF-α in the two groups were decreased compared with those before treatment (P<0.05), and the changes of inflammatory factors in the experimental group were more obvious (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Colloidal pectin bismuth capsule combined with vitacoenzyme tablet in the treatment of patients with CAG has a significant therapeutic effect, can effectively regulate the level of gastric mucosa related and inflammatory factors, and does not increase the incidence of adverse reactions, and has a good clinical application value |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
